{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:58Z","timestamp":1790802418572,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117044","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:53:44Z","timestamp":1789142024000},"page":"117044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups"],"prefix":"10.1016","volume":"247","author":[{"given":"Robbert C.A.M.","family":"Gielen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"van \u2019t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel T.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Vrijaldenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Neijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J.T.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Drukker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ejca.2026.117044_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.117044_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.117044_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117044_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bjc.1987.230","article-title":"Confirmation of a prognostic index in primary breast cancer","volume":"56","author":"Todd","year":"1987","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117044_bib5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","article-title":"Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer","volume":"19","author":"Ravdin","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117044_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13058-017-0852-3","article-title":"An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation","volume":"19","author":"Candido Dos Reis","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"16","key":"10.1016\/j.ejca.2026.117044_bib7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117044_bib8","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practise Guidelines in Oncology: Breast Cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2025. Report No.: Version 5.2025."},{"issue":"2","key":"10.1016\/j.ejca.2026.117044_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117044_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117044_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-020-6534-z","article-title":"MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial","volume":"20","author":"Soliman","year":"2020","journal-title":"BMC Cancer"},{"issue":"6871","key":"10.1016\/j.ejca.2026.117044_bib12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejca.2026.117044_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-017-4262-0","article-title":"A breast cancer gene signature for indolent disease","volume":"164","author":"Delahaye","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ejca.2026.117044_bib14","article-title":"MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data","volume":"9","author":"Brufsky","year":"2025","journal-title":"JNCI Cancer Spectr"},{"issue":"25","key":"10.1016\/j.ejca.2026.117044_bib15","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.117044_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0959-8049(99)00056-8","article-title":"The prognosis of small primary breast cancers","volume":"35","author":"Kollias","year":"1999","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117044_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0959-8049(00)00435-4","article-title":"Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution","volume":"37","author":"D'Eredita","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117044_bib18","unstructured":"Leitlinienprogramm Onkologie. Fr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Berlin: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF); 2025. Report No.: 5.02."},{"key":"10.1016\/j.ejca.2026.117044_bib19","unstructured":"Haute Autorit\u00e9 de sant\u00e9. 2023 update: clinical utility of genomic signatures in early-stage HR-positive\/HER2-negative breast cancer. La Plaine Cedex, France: HAS \u2013 French National Authority for Health; 2024. Report No.: INAHTA Brief Issue 2024."},{"key":"10.1016\/j.ejca.2026.117044_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/11782234241255211","article-title":"Association between Ki-67 proliferative index and oncotype-Dx recurrence score in hormone receptor-positive, HER2-negative early breast cancers. A systematic review of the literature","volume":"18","author":"Mooghal","year":"2024","journal-title":"Breast Cancer (Auckl)"},{"issue":"22","key":"10.1016\/j.ejca.2026.117044_bib21","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ejca.2026.117044_bib22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.21.02019","article-title":"Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial","volume":"40","author":"Lopes Cardozo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9472","key":"10.1016\/j.ejca.2026.117044_bib23","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative G","year":"2005","journal-title":"Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:32:41Z","timestamp":1790800361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S0959804926008257"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117044","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117044"}}